scholarly journals SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy

JCI Insight ◽  
2018 ◽  
Vol 3 (15) ◽  
Author(s):  
Paola Cassis ◽  
Monica Locatelli ◽  
Domenico Cerullo ◽  
Daniela Corna ◽  
Simona Buelli ◽  
...  
Keyword(s):  
Sglt2 Inhibitor ◽  
Podocyte Damage ◽  
Nondiabetic Nephropathy

UHCW audit on SGLT2 inhibitor (SGLT2-i) use

2017 ◽  
Author(s):  
Maria Mytilinaiou ◽  
Georgios K Dimitriadis ◽  
Allan Davasgaium ◽  
Diane Sambrook ◽  
Claire Hewins ◽  
...  
Keyword(s):  
Sglt2 Inhibitor

165-LB: The SGLT2 Inhibitor Canagliflozin Prevents Increased Lipid Oxidation in the Heart following High-Fat Feeding

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 165-LB
Author(s):  
ITZEL FLORES ◽  
CHRIS SHANNON ◽  
MARCEL FOURCAUDOT ◽  
TERRY BAKEWELL ◽  
LUKE NORTON
Keyword(s):  
Lipid Oxidation ◽  
Sglt2 Inhibitor ◽  
High Fat ◽  
Fat Feeding

Fifty-Two-Week Efficacy and Safety of Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Adults with Type 1 Diabetes (inTandem1)

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 212-OR ◽  
Author(s):  
JOHN B. BUSE ◽  
SATISH K. GARG ◽  
JULIO ROSENSTOCK ◽  
TIMOTHY S. BAILEY ◽  
PHILLIP L. BANKS ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Sglt2 Inhibitor ◽  
Efficacy And Safety ◽  
Adjunct Therapy

Effect of an Add-On SGLT2 Inhibitor on the Efficacy of DPP-4 Inhibitor Therapy in Improving Postprandial Hyperglycemia

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 2308-PUB
Author(s):  
TETSUROU ONISHI ◽  
YUKIKO TANIGUCHI ◽  
YUTAKA MORI
Keyword(s):  
Sglt2 Inhibitor ◽  
Postprandial Hyperglycemia ◽  
Inhibitor Therapy

2363-PUB: The Efficacy of Low vs. High FDA-Approved SGLT2 Inhibitor Dose Compared with DPP-4 Inhibitors: A Meta-analysis

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 2363-PUB ◽  
Author(s):  
JARROD UHRIG ◽  
BASEM M. MISHRIKY ◽  
STEPHANIE O. PAGE ◽  
KERRY SEWELL ◽  
JAMES R. POWELL ◽  
...  
Keyword(s):  
Meta Analysis ◽  
Sglt2 Inhibitor ◽  
Inhibitor Dose

451-P: SGLT2 Inhibitor Protects Cardiomyocytes against Palmitate-Induced Lipotoxicity by Increasing Activation of AMPK and Lipid Oxidations

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 451-P
Author(s):  
HAN BYEOL LEE ◽  
SUNGE CHOI ◽  
YUP KANG ◽  
TAE HO KIM ◽  
NAMI LEE ◽  
...  
Keyword(s):  
Sglt2 Inhibitor
Sign in / Sign up

Export Citation Format

Share Document